GSK PLC GSK shares rose 4.69% to £14.63 Wednesday, on what proved to be an all-around favorable trading session for the stock ...

GSK expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter ...

British drugmaker GSK said on Wednesday it is in talks with the Trump administration about ways to lower U.S. drug costs, ...

GSK ( NYSE: GSK) CEO Emma Walmsley said on Wednesday that her company is in discussions with the Trump administration on how ...

Second-quarter sales rose to £7.99 billion from £7.88 billion in the same period the year prior.

GSK Plc reported better-than-expected profit and raised its estimates for revenue at two key divisions in a report that ...

GSK’s anti-TIM monoclonal antibody (mAb) cobolimab has failed a Phase III trial in non-small cell lung cancer (NSCLC). The ...

GSK's GSK +0.59% Get Free Report short percent of float has fallen 27.17% since its last report. The company recently reported that it has 13.51 million shares sold short, which is 0.67% of all ...

GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...